SCHEMBL3293573

SCHEMBL3293573

CCOC(=O)c1cn(-c2ccccc2)c2nc(S(C)(=O)=O)ncc2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPK1 P28482 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 1/20 0.44
XBP1 P17861 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TLR9 Q9NR96 1/20 0.44
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
TSHR P16473 1/20 0.43
PIM1 P11309 1/20 0.42
IRAK1 P51617 1/20 0.42
CAMK2B Q13554 1/20 0.42
CAMK2G Q13555 1/20 0.42
CAMK2D Q13557 1/20 0.42
PIM3 Q86V86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4574269 0.91 CSF1R (0.46) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL16088468 0.89 PDE4A (0.46) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL4573769 0.88 CSF1R (0.43) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL3533125 0.84 MAPK1 (0.51) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL3289501 0.84 CSF1R (0.65) CSF1RSRC
SCHEMBL3290264 0.83 ALDH1A1 (0.53) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL8803409 0.82 ALDH1A1 (0.42) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL30585778 0.82 ALDH1A1 (0.42) CSF1RALDH1A1MAPK1MAPTNPC1
SCHEMBL28537798 0.81 CSF1R (0.62) CSF1RMAPTNPC1SRC
SCHEMBL16088470 0.81 CSF1R (0.44) CSF1RALDH1A1MAPK1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012466-B2 Substituted tricyclic pyrazolo-pyrimidine compounds ARQULE INC. (US) 2015-04-21 US disclosed
US-9012466-B2 Substituted tricyclic pyrazolo-pyrimidine compounds ARQULE INC. (US) 2015-04-21 US disclosed
WO-2014164729-A1 SUBSTITUTED TRICYCLIC PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2014-10-09 WO disclosed
US-20140275023-A1 Substituted Tricyclic Pyrazolo-Pyrimidine Compounds ARQULE, INC. 2014-09-18 US disclosed
US-20140275023-A1 Substituted Tricyclic Pyrazolo-Pyrimidine Compounds ARQULE, INC. 2014-09-18 US disclosed
US-7728003-B2 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-01 US disclosed
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1945637-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-23 EP disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed
WO-2008055013-A2 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 WO disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE FLT3, FES, ALK CSF1R 430/4885ALDH1A1 3103/4885MAPK1 249/4885
US-20140275023-A1 Substituted Tricyclic Pyrazolo-Pyrimidine Compounds TYMP, DPYD, TYMS CSF1R 3892/4885ALDH1A1 1413/4885MAPK1 2505/4885
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 598/4885ALDH1A1 3735/4885MAPK1 514/4885
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 427/4885ALDH1A1 3590/4885MAPK1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.